General Information
Akros Diabetes 002
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients with Type 2 Diabetes Mellitus.
| Protocol | |
|---|---|
| Identifier | AT851-U12-002 |
| UID | 41dbb5ed-581a-4ff9-82a9-1483db4ce36a |
| Status | Done - Archived |
| Phase | 2 |
| Category | Diabetes Type 2 / Adult |
| Launch Year | 2012 |
| NCT Number | - |
| Created | 2012-06-08 16:55 |
| Last Updated | 2012-06-08 16:55 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2012-12-31 | No |
| Enrollment Open | 2012-10-08 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2012-10-08 | No |
| PI Meeting Start | 2012-10-04 | No |
| PI Meeting End | 2012-10-05 | No |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2013-05-30 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Martinez, Gilbert | GJMartinez | No |
| Recruiter | - | No | |
| Coordinator | Yela, Susie | SYela | No |
| Regulatory | Aguirre, Sandra | SAguirre | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Akros Pharma Inc. |
|---|---|
| Division | Akros Pharma Inc. |
| Team | Akros Pharma Inc. |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | IRB ID No. MED1-12-262 |
|---|---|
| CRO | Medpace, Inc. |
| CRO Ref | SIV waived as PI attended IM (10/04 &05/12) |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
